Rubicon Research Limited has announced the acquisition of an 85% equity stake in Arinna Lifesciences Limited, marking its strategic entry into the Indian domestic formulations market, with a strong focus on central nervous system (CNS) therapies. Arinna Lifesciences, a domestic formulations company, has a portfolio of over 60 brands focused on chronic therapies, particularly CNS-related conditions. The company is supported by a network of more than 4,000 prescribers and a well-established distribution ecosystem across India.
This acquisition aligns with Rubicon’s strategy to leverage its intellectual property, chronic product portfolio, and R&D capabilities to expand into high-growth markets. By integrating Arinna’s sales and distribution network, Rubicon aims to enhance access to its differentiated offerings, including specialty products and drug-device combinations.
Parag Sancheti, CEO of Rubicon Research, stated that the acquisition provides a strong platform to deploy the company’s proven growth model in the Indian market. He highlighted Rubicon’s track record of scaling its U.S. business and successfully integrating acquisitions to expand into new segments such as branded specialty products and nasal drug delivery systems.
The transaction values Arinna at an enterprise value of INR 200 crore on a cash- and debt-free basis. After adjustments, the purchase consideration for the 85% stake is approximately INR 175.92 crore. The deal is expected to close within 30 days, subject to customary conditions. Following the acquisition, Arinna’s founder, Vivek Seth, will retain a 15% stake and continue as Managing Director, ensuring continuity in leadership and operations.
Founded in 1999, Rubicon Research is a vertically integrated pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated pharmaceutical products. With a portfolio of over 80 products and globally regulated manufacturing facilities, the company continues to expand its presence across key therapeutic segments, including CNS.